A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

Clinical trial NCT05324410 · COMPLETED

Trial details

NCT number: NCT05324410
Sponsor: Vertex Pharmaceuticals Incorporated
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

APOL1-mediated Kidney Disease

Start date: 2022-04-07
Primary completion: 2022-11-07
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.